Today's Trend
Cogent Biosciences (COGT) — The stock is trading lower amid mixed signals: bullish analyst ratings and price targets have been offset by downward EPS revisions and a large fourth‑quarter institutional sell‑off. Volume is elevated, suggesting active repositioning by investors.
- HC Wainwright remains constructive — the firm keeps a "Buy" rating and a $52 price target on COGT, which supports upside expectations despite model changes. HC Wainwright Note
- Wedbush reiterated an "Outperform" rating, signaling continued analyst confidence that could limit downside and attract risk‑tolerant investors. Wedbush Reiterates Outperform
- Recent analyst coverage included a $42.82 consensus price target from brokerages, giving a clear reference point for upside from current levels. Price Target Note
- Short‑interest reports show anomalous values (reported as 0 shares with NaN changes and 0.0 days‑to‑cover), indicating either no material short exposure or a data/reporting issue — not currently a clear driver.
- Boone Capital sold 945,042 shares in Q4, reducing its position value by about $13.6M — a meaningful institutional sale that can weigh on the stock, particularly in the near term. Boone Capital Sale
- HC Wainwright trimmed EPS forecasts for multiple 2026 quarters and lowered FY2026 estimates (they still maintain a Buy), which implies weaker near‑term profitability expectations and is a likely contributor to selling pressure. HC Wainwright Estimates
Investor takeaway: downward EPS revisions and a large institutional sale are the main bearish catalysts pressuring COGT today, while strong analyst ratings and multi‑dozen dollar price targets provide counterbalancing upside narratives. Monitor follow‑up filings (13F, 13D/G), upcoming clinical/operational catalysts, and volume/short‑interest updates for which signal will dominate next.